Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NMRC-MV-Ad-PfC + NMRC-M3V-Ad-PfCA
- Development stage
- Unknown
- Lead developer
- Naval Medical Research Center
- Modality
- Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**NMRC-MV-Ad-PfC + NMRC-M3V-Ad-PfCA** is an investigational combination malaria vaccine composed of two replication-deficient recombinant adenovirus serotype 5 vectors. One vector (NMRC-MV-Ad-PfC) encodes the *Plasmodium falciparum* circumsporozoite protein (CSP), and the other (NMRC-M3V-Ad-PfCA) encodes both CSP and apical membrane antigen-1 (AMA1) from the 3D7 strain of *P. falciparum*. Both vaccine components are designed to elicit robust cell-mediated (primarily CD8+ T cell) and humoral immune responses against key malaria antigens, targeting both pre-erythrocytic (CSP) and erythrocytic (AMA1) parasite stages. The vaccine regimen involves co-formulating equal amounts of each vector and administering them together via intramuscular injection. The vaccine has been evaluated in Phase 1 and 2a clinical trials for safety, tolerability, immunogenicity, and efficacy in healthy, malaria-naïve adults, and is noted for its strong T cell immunogenicity, though it has not achieved sterile protective immunity in challenge studies[1][4][5][7][8][10].
- Other names
- NMRC-M3V-Ad-PfCANMRC-M-3V-Ad-PfCANMRC-M 3V-Ad-PfCANMRC-MV-Ad-PfC
02
Targets
CSP (Circumsporozoite protein)AMA1 (Apical membrane antigen 1)
Beyond the preview
Go deeper on NMRC-MV-Ad-PfC + NMRC-M3V-Ad-PfCA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NMRC-MV-Ad-PfC + NMRC-M3V-Ad-PfCA.